/PRNewswire/ Envisagenics, Inc., a New York-based biotechnology company leveraging artificial intelligence (AI) and RNA-splicing analytics for discovery and.
Envisagenics Raises Series A Financing to Scale Its AI-powered RNA Splicing Drug Discovery Platform prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Biogen and Envisagenics to advance RNA splicing research for CNS diseases
Envisagenics’ SpliceCore platform can be used to identify, test and validate RNA splicing errors at scale
Biogen and Envisagenics are collaborating to advance ribonucleic acid (RNA) splicing research within the central nervous system (CNS) diseases area.
Biogen will utilise Envisagenics’ artificial-intelligence (AI)-driven RNA splicing platform – known as SpliceCore – in order to define and gain an understanding of the regulation of different RNA isoforms in CNS cell types.
In the process of RNA splicing, extra information embedded in the intermediate RNA molecules is trimmed, with this trimmed RNA then used to produce functional proteins.